Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?

Objective. Interstitial lung disease (ILD) is rare, but it is one of the most frequent extra-articular manifestations and a relevant cause of morbidity and mortality in rheumatoid arthritis (RA). Over the past few years, Janus kinase inhibitors (JAKis) have been reported to have promising efficacy...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Beatrice Maranini, Roberta Foti, Moustapha Taha, Veronica Venturelli, Andrea Lo Monaco, Marcello Govoni
Formato:	Artigo
Idioma:	Inglês
Publicado em:	PAGEPress Publications 2025-01-01
coleção:	Reumatismo
Assuntos:	JAK inhibitors interstitial lung disease ILD rheumatoid arthritis RA
Acesso em linha:	https://www.reumatismo.org/reuma/article/view/1754
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!